Galectin Therapeutics Completes Enrollment of Second Cohort of Phase 1 Trial of GR-MD-02 for NASH (Fatty Liver Disease) With

Galectin Therapeutics Completes Enrollment of Second Cohort of Phase 1 Trial
of GR-MD-02 for NASH (Fatty Liver Disease) With Advanced Fibrosis

NORCROSS, Ga., April 23, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics
(Nasdaq:GALT), the leading developer of therapeutics that target galectin
proteins to treat fibrosis and cancer, announced today that all eight (8)
patients have received their first infusion in cohort 2 of its Phase 1
clinical trial of GR-MD-02 in patients with NASH with advanced fibrosis.
Patients in cohort 2 were successfully dosed with 4 mg/kg, which is double the
dose given in cohort 1. The clinical trial protocol specifies that eight
patients are included in cohort 2; however, an additional two patients may be
enrolled to ensure the requisite number of eight patients complete the 63-day
protocol in the second cohort.

As with all phases of the clinical trial, this cohort was initiated in full
compliance with the rules, regulations and specific conditions set forth by
the U.S. Food and Drug Administration (FDA) for this Phase 1 clinical trial.
The second cohort follows highly successful results from the first cohort
showing that 2 mg/kg was safe and very well tolerated, and that GR-MD-02
treatment resulted in significant improvement in multiple biomarkers of
fibrosis and liver inflammation in patients with NASH with advanced fibrosis.
(see full results at:
In addition to serum biomarkers, patients will be evaluated with FibroScanĀ®
when available, an FDA-approved ultrasound method for evaluating liver tissue
stiffness, to gain experience in this method for evaluating liver fibrosis.
The Company anticipates reporting the results of cohort 2 around the end of
July 2014.

"We are pleased that enrollment of the second cohort was completed very
rapidly, which speaks to the urgent need to identify an effective treatment
for fatty liver disease with advanced fibrosis," said Dr. Peter G. Traber,
President, Chief Executive Officer, and Chief Medical Officer of Galectin
Therapeutics Inc. "The goal of therapy with GR-MD-02 in NASH patients with
advanced fibrosis is the reversal of fibrosis and prevention of complications
of cirrhosis and liver transplantation."

The trial is titled, "A Multi-Center, Partially Blinded, Maximum Tolerated
Multiple Dose Escalation, Phase 1 Clinical Trial to Evaluate the Safety of
GR-MD-02 in Subjects with Non-Alcoholic Steatohepatitis (NASH) with Advanced
Hepatic Fibrosis." Trial design details can be found at In 2013,
Galectin Therapeutics received Fast Track designation from the FDA for this
clinical development program. FDA grants Fast Track designation to help
expedite review and approval of drugs in development that treat serious or
life threatening diseases and fill an unmet medical need.

About Fatty Liver Disease with Advanced Fibrosis

Non-alcoholic steatohepatitis (NASH), also known as fatty liver disease, has
become a common disease of the liver with the rise in obesity rates, estimated
to affect nine to 15 million people, including children, in the U.S. Fatty
liver disease is characterized by the presence of fat in the liver along with
inflammation and damage in people who drink little or no alcohol. Over time,
patients with fatty liver disease can develop fibrosis, or scarring of the
liver, and it is estimated that as many as three million individuals will
develop cirrhosis, a severe liver disease where liver transplantation is the
only current treatment available. Approximately 6,300 liver transplants are
done on an annual basis in the U.S. There are no drug therapies approved for
the treatment of liver fibrosis.

About Galectin Therapeutics

Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based
therapies for the treatment of fibrotic liver disease and cancer based on the
Company's unique understanding of galectin proteins, key mediators of biologic
function. We are leveraging extensive scientific and development expertise as
well as established relationships with external sources to achieve cost
effective and efficient development. We are pursuing a clear development
pathway to clinical enhancement and commercialization for our lead compounds
in liver fibrosis and cancer. Additional information is available at

Forward Looking Statements

This press release contains, in addition to historical information,
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements relate to future events or
future financial performance, and use words such as "may," "estimate,"
"anticipated," "expect" and others. They are based on our current expectations
and are subject to factors and uncertainties, which could cause actual results
to differ materially from those described in the statements. These statements
include those regarding the clinical trial, including the expected timing of
results for the second cohort, and potential benefits and therapeutic effects
of GR-MD-02. Factors that could cause our actual performance to differ
materially from those discussed in the forward-looking statements include,
among others, that we may not be successful in developing effective treatments
and/or obtaining the requisite approvals for the use of GR-MD-02 or any of our
other drugs in development. Our current clinical trial and any future clinical
studies may not produce positive results in a timely fashion, if at all, and
could prove time consuming and costly. We may have difficulty enrolling new
patients in additional trials, which could impact timing and costs. Results
from the first cohort of Phase 1 are not necessarily indicative of future
results in the clinical trial. Plans regarding development, approval and
marketing of any of our drugs are subject to change at any time based on the
changing needs of our company as determined by management and regulatory
agencies. Regardless of the results of any of our development programs, we may
be unsuccessful in developing partnerships with other companies that would
allow us to further develop and/or fund any studies or trials. To date, we
have incurred operating losses since our inception, and our ability to
successfully develop and market drugs may be impacted by our ability to manage
costs and finance our continuing operations. For a discussion of additional
factors impacting our business, see our Annual Report on Form 10-K for the
year ended December 31, 2013, and our subsequent filings with the SEC. You
should not place undue reliance on forward-looking statements. Although
subsequent events may cause our views to change, we disclaim any obligation to
update forward-looking statements.

CONTACT: Galectin Therapeutics Inc.
         Peter G. Traber, MD, 678-620-3186
         President, CEO, & CMO

Galectin Therapeutics, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.